BIOCHEMICAL GENETICS
PART II
(LYSOSOMAL STRAGE DISORDERS)

By:

Dr. Preeti Bajpai

Lysosome as dynamic cell regulator



Source: Ballabio, A., Bonifacino, J.S. Lysosomes as dynamic regulators of cell and organismal homeostasis. *Nat Rev Mol Cell Biol* **21,** 101–118 (2020)

Lysosomal Storage Diseases

- Metabolic disorders
- Recessive inheritence
- Caused due to progressive accumulation of toxic material
- Almost 50 disorders are known till date
- Affecting different parts of the body viz. skeleton, brain, skin, heart, and central nervous system.
- Treatment available for very few disorders.

PRIMEVIEW

LYSOSOMAL STORAGE DISORDERS

nature REVIEWS DISEASE PRIMERS

For the Primer, visit doi:10.1038/s41572-018-0031-6

Lysosomal storage disorders (LSDs) are a group of inherited metabolic disorders that are characterized by the accumulation of macromolecules inside lysosomes. Lysosomes engulf and break down macromolecules, including nucleic acids, proteins, carbohydrates and lipids, inside cells. LSDs are multi-system diseases that frequently involve pathology in the brain.

EPIDEMIOLOGY

Collectively, LSDs are relatively common disorders (1: 5,000 live births), although individual disorders are rare and have an incidence between 1 in 50,000 and 1 in 250,000 live births. The most common disorders are Gaucher disease and the neuronal ceroid lipofuscinoses.

The incidence of some LSDs can be higher in specific populations owing to a genetic founder effect, such as Tay–Sachs disease in the Ashkenazi Jewish population

SCREENING

In the United States, carrier screening for Tay–Sachs disease in the Ashkenazi Jewish community has reduced the incidence of this disorder by 90% in this population. However, universal newborn screening for LSDs is only available in a few countries worldwide.

Preimplantation genetic diagnosis can be offered to couples who have a child with an LSD and for whom the disease-causing mutation has been ascertained

MECHANISMS



Mutations in genes involved in lysosomal function leads to the aberrant processing, degradation and accumulation of macromolecules inside lysosomes

The consequences of macromolecule accumulation vary between LSDs and depend on the type of stored material and cell

Some mechanisms common to multiple LSDs have been identified and include inflammation, cell death, oxidative stress, and defects in cellular transport and calcium homeostasis

OUTLOOK

Most LSDs do not have an approved therapy, and supportive therapy is the only option. However, many new therapies are being evaluated pre-clinically and in clinical trials, including proteostasis modifiers, anti-inflammatory therapies and gene therapy. Indeed, several gene therapies that use viral vectors to deliver normal lysosomal genes are being trialled in patients.

DIAGNOSIS

LSDs can be sub-classified as, for example, enzyme deficiency disorders, post-translational modification defects, integral membrane protein disorders, and lysosome-related organelle disorders. In general, diagnosis is based on clinical presentation and results from laboratory tests. For example, enzyme assays can be carried out to diagnose lysosomal enzyme deficiency disorders, followed by genetic testing to identify the specific disease-causing mutation(s). Some LSDs can only be diagnosed by mutation analysis.

In general, most LSDs present during infancy or childhood, although adult-onset forms do occur. Symptoms affect multiple organ systems, and depend on the genetic defect and the resulting stored macromolecules.

MANAGEMENT

Approved therapies are available for some LSDs, although their efficacy is variable. Approved therapies include replacing the defective enzyme (enzyme-replacement therapy), reducing the accumulation of macromolecules (substrate reduction therapy) or improving the function of the defective enzyme (chaperone therapy). For LSDs without an approved therapy, supportive care is available and depends on the patient's clinical manifestations.

doi:10.1038/s41572-018-0031-6

Written by Louise Adams; designed by Laura Marshall

Source: https://www.nature.com/articles/s41572-018-0031-6

- The lysosome is cell's recycling center as it processes unwanted material into substances that the cell can use.
- The break down of complex substances is carried out with the help of enzymes.

.

Mucoploysaccharides

Sphingolipids

Glycolipids

Proteins



Metabolites

Mutation in gene leads to lysosomal dysfunction resulting in progressive accumulation of substances

Cystinosis

- Cystine = breakdown product of protein degradation

Cystinosis

Abnormal Condition

- **Defective lysosomal transport protein Cystinosin**
- **Accumulation of Cystine**
- **Gene located on chromosome 17**
- **Three forms: 1) Nephropathic (Infants); 2) Late-onset (Juvenile); 3) Adult (Benign)**
- **Pathology: Impaired kidney function, increased sensitivity to light, and marked growth retardation**

Fabry Disease

- Due to deficiency of the enzyme **Alpha Galactosidase A**
- Accumulation of **Ceramide trihexoside**
- **X linked inheritance (males more severely affected)**
- **Most common disorder**
- **Symptoms: Skin rashes, Neropathic pain, Angiokeratomas and renal failure**



Skin of a patient

Gaucher's Disease

- Due to deficiency of the enzyme **glucerebrosidase**
- Accumulation of **glucocerebroside**
- Location on **chromosome 1**
- **Splenomegaly**- most common finding
- **Osteonecrosis** of femoral head
- Tissue paper cytoplasm



Hurler's Disease

- Mucoploysaccharide Type I disorder
- Caused due to defeciency of enzyme Alpha-L-Iduronidase
- **Leads to accumulation of Heparin sulphate and Dermatan sulphate**
- Chromosome 4
- Symptoms: Skeletal abnormality, hepatosplenomegaly and severe intellectual disability, **CORNEAL CLOUDING**



Source: Wikipedia

Hunter's Syndrome

- **Also known as Mucopolysaccharide Type II disease**
- **Caused due to deficiency of enzyme Iduronate 2-Sulfatase**
- **Leads to accumulation of Heparin sulphate and Dermatan sulphate**
- **X linked disorder**
- **Enzyme replacement, Bone marrow transplantation and gene therapy available for this disorder**

Sanfilopo syndrome

- **MPS type III**
- **Four subtyes (A, B, C & D)**
  - **A: Heparin Sulfate Sulfatase (HSS)**
  - **B: N-acetyl-alpha-d-glucosaminidase (NAGLU)**
  - **C: acetyl-CoA: alpha-glucosaminide n-acetyl transferase (HGSNAT)**
  - **D: N-acetylglucosamine-6-sulfate sulfatase (GNS)**

– All lead to accumulation of Heparin sulfate

– Characterized by progressive CNS degeration

Developmental delay, sleep disorder, hyperactive

Source: https://en.wikipedia.org/wiki/Sanfilippo_syndrome

Krabbe's Disease

- **Also known as Globoid cell Leukodystrophy**
- **Due to deficiency of enzyme Beta Galactocerebrosidase**
- **Leads to an accumulation of Galactocerebroside**
- **Destruction of myelin sheath**
- **Symtoms include- muscular stiffness, loss of head control, fever without infection, seizures**



Globoid cell cytoplasm
Source: Biocehmistry @ Muhlenburg

Niemann-Pick Disease

- **Most prevalent in Ashkenazi Jews**
- **Due to deficiency of enzyme Sphingomylinase**
- **Leads to accumulation of Sphingomyelin**
- **Type A and B: Hepatospleenomegaly**
- **Type C: Dementia and depression**
- **Characteristic Cherry Red Spot on Macula**



Source: Treasure Island (FL): StatPearls Publishing; 2020

Tay- Sach's Disease

- Due to deficiency of **Hexosaminidase A**
- Leads to an accumulation of **GM2 ganglioside**
- Increased prevalence in **Ashkenazi Jews**
- **"Cherry Red Spot" in Macula**
- **No hepatosplenomegaly**



Source: Wikipedia



Source: https://edu.glogster.com/glog/tay-sachs-worst-disease-ever/1nk3813lu9d

Diagnosis

- Enzyme assay for most of the disorders
  - Fluorometry, Tandom Mass Spectrometry
- Mutation analysis may be performed for certain disorders.
- RFLP PCR, DNA sequencing, Multiplex ligation-dependent probe amplification



Source: https://maegawa.research.pediatrics.med.ufl.edu/lsd-program/what-are-lysosomal-storage-diseases/

- Thank you